The Stock Declines as the Truth is Revealed On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the "negative impact" of the Indore facility's failed inspection would lower 2025 revenue by "approximately $500 million" and 2025 earnings from operations by "approximately$385 million." The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from ...